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The 1D-adrenergic receptor (1D-AR) is involved in angiotensin II (Ang II)-induced 
vascular remodeling and hypertension. Whether 1D-AR plays a role in hypertension-
associated cardiac hypertrophy is unclear. Here we investigated effects of BMY 7378, an 
1D-AR antagonist, on cardiac status in aged spontaneously hypertensive rats (SHR). Male 
SHR were studied during the phase of developing hypertension (5 and 10-weeks-old) and 
once hypertension was established (20 and 30 weeks old) to assess the evolution of cardiac 
hypertrophy. Age-matched WKY rats were studied as controls.   30 week-old SHR were 
treated for 4 weeks with BMY 7378 (10 mg.kg-1.day-1, o.a.), or captopril (angiotensin 
converting enzyme inhibitor, 40 mg.kg-1.day-1, o.a.) (as a positive control). Blood pressure 
and cardiac function were measured in vivo, cardiac hypertrophy by histology, and 1D-AR 
protein expression by immunofluorescence. By 30 weeks of age, SHR exhibited significant 
hypertension and cardiac hypertrophy. BMY 7378 and captopril decreased blood pressure 
and improved hemodynamic parameters and cardiac function in treated SHR versus untreated 
SHR (p<0.05).  Histology showed increased cardiomyocyte size, fibrosis, and left ventricular 
hypertrophy in SHR hearts. BMY 7378 ameliorated fibrosis and cardiac hypertrophy, but 
had no effect on cardiomyocyte size in SHR. Effects of BMY 7378 were associated with  
increased 1D-AR protein expression in SHR. Our data indicate that pharmacological 
inhibition of 1D-AR reduces blood pressure and associated cardiac hypertrophy in aged 
SHR. These findings suggest that the 1D-AR system plays a pathophysiological role in the 
development of hypertension and cardiac target organ damage in SHR.  
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Hypertension is a chronic non-communicable disease that affects 1.3 billion people 
worldwide (1). Hypertension promotes hypertensive heart disease (HHD), which manifests 
clinically as functional and structural changes with systolic and diastolic ventricular 
dysfunctiis associated with  poor prognosis and patients are at risk of myocardial infarction, 
congestive heart failure, stroke and sudden death  (2). 
Spontaneously hypertensive rats (SHR), a genetic model of human hypertension, develop 
target organ damage as they age. Undelying pathophysiological processes include activation 
of the renin angiotensin system (RAS) (3,4) because  treatment with angiotensin converting 
enzyme inhibitors prevented hypertension, left ventricular hypertrophy and vascular 
remodeling in young SHR (5), and reduced BP, fibrosis and cardiac weight in older SHR (6). 
Activation of the sympathetic nervous system has also been implicated in SHR (reference). 
It is possible that functional and molecular interactions between the RAS and the adrenergic 
system could modulate cardiovascular responses in SHR (7,8). For example, angiotensin II 
(Ang II) promotes expression of the 1D-adrenergic receptor (1D-AR) in vascular smooth 
muscle cells (9,10), while inhibiting ACE decreased both 1D-AR expression and vascular 
function in pre-hypertensive SHR (11), and in aryl hydrocarbon receptor null mice (another 
model of hypertension) (12). 
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1D-ARs, expressed primarily in vascular cells (13,14), plays a role in vascular hypertrophy, 
as evidenced in vivo and in vitro by increased media thicknes and protein synthesis (10,15). 
Ang II infusion in rats promoted an increase in media thickness and media-to-lumen ratio in 
aorta, where 1D-AR predominates, but not in tail arteries where 1A-AR is the main receptor 
subtype expressed (16). BMY 7378, an 1D-AR antagonist reversed Ang II-induced aortic 
remodeling (16). 1D-AR knockout mice exhibit thinner vascular walls and  cardiac ventricles 
than control wildtype mice (17,18). These mice also have lower blood pressure than control 
counterparts. Together these findings suggest that the α1D-AR system is involved in vascular 
remodeling in hypertension.  
Despite the growing evidence that signaling through α1D-ARs is important in vascular 
changes in hypertension, there is a paucity of information regarding its significance in 
hypertension-associated cardiac remodeling.  To address this, we questioned whether SHR 
myocardium expresses α1D-AR and whether BMY 7378, a pharmacological inhibitor of α1D-
AR, influences cardiac remodeling in hypertension. 
Materials and Methods 
Animals 
Male Wistar Kyoto rats (WKY) and SHR of 5, 10, 20 and 30 weeks of age were obtained 
from the breeding colony of the Institute of Cell Physiology (UNAM). Three or four rats of 
each age were housed per cage and maintained in a pathogen-free environment under 
controlled conditions (22 ± 2°C, 40-60% humidity, 12-h/12-h light/dark cycle), with food 
and water ad libitum.  The Bioethics Committee of our institution approved all procedures 
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and we followed Mexican Official Norm about technical specifications for the production, 
care, and use of laboratory animals (NOM-062-ZOO-1999, Ministry of Agriculture). 
Blood Pressure and Heart Rate Recordings 
A time-course of the increase in BP was conducted in rats of 5, 10, 20 and 30 weeks of age 
to observe the progression of hypertension, measuring BP through a non-invasive, indirect 
method with a tail-cuff device (Automatic Blood Pressure Computer, Model LE5007; Letica, 
Panlab, Spain). Rats were trained for 1 week inside a plastic restrainer at 37°C; then, a sensor 
and an inflatable latex ring were placed on the rat's tail to obtain BP recordings. An average 
of five readings was used to obtain heart rate (HR), systolic blood pressure (SBP), diastolic 
blood pressure (DBP), and mean arterial pressure (MAP).  
Histology 
After BP recordings, histological analysis to examine  development of LVH in SHR at 
different ages was conducted. Rats were anesthetized with sodium pentobarbital (50 mg/kg 
i.p.) and perfused with phosphate buffered saline solution (0.88 % NaCl, 0.14 % Na2HPO4, 
and 0.02 % NaHPO4, pH 7.4), and then with a 4% formaldehyde-phosphate buffer solution. 
The heart was removed and maintained in a cryoprotective 4% formaldehyde-10% sucrose-
0.1M DMSO solution for at least 24 h. This solution was replaced by a 30% sucrose solution 
at 4°C for at least 3 h. Thereafter hearts were embedded in Tissue-Tek O.C.T. mounting 
media compound (Sakura Finetek, Inc., Torrance, CA, USA), and frozen in acetone cooled 
with dry ice. Six-micrometer sections were cut on a cryostat at -25°C (Leica Microsystems, 
Wetzlar, Germany) with a cross-sectional orientation, all slices were taken at the same height 
and we took as reference the papillary-muscle of the left ventricle. Sections were applied to 
1% gelatinized slides and stored at -20°C until use or were stained with Masson's Trichrome 
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(for detection of fibrosis in 30-week-old rats) or hematoxylin and eosin (H&E); slices were 
analyzed in an optical microscope. The left ventricular thickness was measured using ImageJ 
software, ver.2.1.4.5 (National Institutes of Health, Bethesda, MD, USA), and the area (μm2) 
of cardiomyocyte was measured in fields that include papillary muscle and the vertically 
aligned muscle layers adjacent to it, measuring the major and minor transverse axes of 
cardiomyocytes to estimate the cross-sectional area using the ZEN 2012 software (Carl Zeiss 
Laser Scanning systems LSM 510, Oberkochen, Germany) (19). 
BMY 7378 and Captopril Administration 
30 weeks-old rats were randomly separated, and four groups were formed (n = 3-4 rats each): 
Control groups of WKY and SHR were orally administered with 0.5 mL of saline solution; 
SHR + BMY 7378 group (selective 1D-AR antagonist, 10 mg.kg
-1.day-1; 8-[2-[4-(2-
methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione; Sigma-Aldrich, St. 
Louis, MO, USA), and the SHR + captopril group (ACE inhibitor, 40 mg.kg-1.day-1; S-1-(3-
mercapto-2-methyl-1-oxopropyl)-L-proline; Sigma-Aldrich). Drugs were dissolved in saline 
solution and administered with a cannula daily for 4 weeks. 
Cardiac Function Measurement  
After 4 weeks of treatment, rats were anesthetized with sodium pentobarbital (50 mg.kg-1 
i.p.), and the right carotid artery was exposed at a length of 5 mm. A heparin-coated catheter 
(PE10) was advanced into the left ventricle through the right carotid artery; the correct 
position of the catheter tip in the left ventricle was then confirmed by visualizing the 
waveform of the left ventricular (LV) pressure. The arterial line was connected to the 
computerized data-acquisition system (model MP100WSW; Biopac Systems Inc., Santa 
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Barbara, CA, USA) to record left ventricular end diastolic pressure (LVEDP), left ventricular 
systolic pressure (LVSP) and maximal rates of LVP rise and fall (± dP/dt) (20). 
A catheter was also inserted into the left jugular vein for drug administration, and a dose-
response curve to isoproterenol ((−)-isoprenaline hydrochloride; Sigma-Aldrich) was 
constructed in graded doses ranging from 0.75 - 6 ng.kg-1 i.v. Isoproterenol doses were 
administered after each LV hemodynamic measurement returned to baseline (21). The 
recording and reading of data were analyzed using AcqKnowledge software, ver.3.9.1 
(Biopac Systems, Inc.). At the end of each experiment, the catheter was cut, and the heart 
was removed to verify that the catheter was inside the ventricle. After dose-response curves, 
the histological procedure was developed as mentioned. 
Immunofluorescence 
Slices were washed 10 minutes with PBS and incubated with collagenase II (cat. CLS 2, 
Worthington, Lakewood, NJ, USA) for 3 hours at 37°C to decrease extracellular matrix; then, 
slices were washed 3 times 10 minutes each, and subjected to a heat-induced epitope retrieval 
in a solution of Tris 20 mM and 2% of SDS, pH 9 at 90°C for 15 minutes, and then exposed 
to UV radiation for at least 6 hours to decrease background fluorescence. Slices were washed 
3 times 10 min each with PBS and incubated with blocking solution (3% fetal bovine serum 
and 0.3 % Triton X100 in PBS) at room temperature for 1 hour. After removal of the blocking 
solution, primary rabbit anti- α1D-AR was applied at 1:1500 in blocking solution and left 
overnight at 4°C in a humidity chamber (22). The slices were washed with PBS followed by 
exposure of a secondary goat anti-rabbit antibody coupled to Alexa Fluor 488 (cat. A11034, 
Invitrogen, Eugene, OR, USA) at 1:1000, and incubated 1 hour at room temperature in 
humidity chamber. Secondary antibody was removed by washing with PBS and slices were 
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covered with Vectashield antifade mounting medium (cat. H-1000, Vector laboratories, 
Burlingame, CA, USA) added with 0.1% of Hoechst 33342 nucleic acid stain (cat. H1399, 
Thermo Fisher Scientific, Waltham, MA, USA), then a glass coverslip was applied. The 
tissue sections were examined with a fluorescence microscope (Carl Zeiss Laser Scanning 
systems LSM 510, Oberkochen, DE) with 200X amplification. Fluorescence was determined 
adjusting a threshold to exclude background fluorescence, and gated to include intensity 
measurements only from positively stained tissues using the area of the whole stained tissue 
section, measurements were obtained using ImageJ software, ver.2.1.4.5 (National Institutes 
of Health, Bethesda, MD, USA). 
Statistical Analysis 
Data are presented as the mean ± standard error of the mean (SEM) of 3-4 rats per group.  
A Student’s-t test was developed for comparisons between WKY and SHR; analysis of 
repeated measures (analysis of variance, ANOVA) for dose-response curves; and one-way 
ANOVA for histological and immunofluorescence analysis were carried out, both ANOVA 
with a Bonferroni post-hoc test. Differences were considered statistically significant when p 
< 0.05 (#p < 0.05 vs. WKY or *p < 0.05 vs. SHR). All the images and the statistical analysis 
were performed employing the Systat SigmaPlot Statistical Software, ver.12.0 (SSI, San 
Jose, CA, USA). 
Results 
Blood Pressure 
Mean base line SBP, DBP, and MAP were not significantly different between WKY and 
SHR at  5 and 10 weeks of age. In contrast, all of these parameters were significantly higher 
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in SHR of 20 and 30-week-old compared with control WKY  (#p < 0.05) (Table 1). In SHR, 
(5 to 30 weeks of age), HR was significantly higher versus age-matched WKY (#p < 0.05) 
(Table 1). 
Four week oral administration of BMY 7378 or captopril to SHR of 30 weeks of age 
decreased BP within  1 week, with the BP decrease being even greater from week 2 post-
treatment (*p < 0.05). Neither BMY 7378 nor captopril modified HR (p > 0.05) (Table 2).  
Histology   
The cross-sectional slices at the papillary-muscle level revealed the right and left cardiac 
ventricles. In SHR from 20 weeks of age, wall thickness of the left ventricle was increased 
versus WKY and by 30 weeks there was clear concentric hypertrophy (Figure 1a). 
Quantitative analysis of  cardiomyocyte size (Figure 1b) and left ventricular wall thickness 
(Figure 1c) demonstrated that both were greater in SHR versus WKY (p < 0.05). 
Treatment with either BMY 7378 or captopril, during 4 weeks, diminished left ventricular 
thickness (Figure 2a) and reduced fibrosis in 30-week-old SHR (Figure 2b). Quantitative 
analysis showed that BMY 7378 or captopril decreased the left ventricular wall in 
comparison with control SHR (p < 0.05) (Figure 2c); there was no difference between WKY 
and SHR + BMY 7378 groups (p > 0.05) (Figure 2c). However, the ventricular wall of SHR 
rats treated with captopril was even thinner than in WKY (p < 0.05) (Figure 2c). There were 
no significant changes in cardiomyocyte size in the groups treated with BMY 7378 or 
captopril vs. SHR (p > 0.05) but there were significant differences between treatments groups 
vs. WKY (p < 0.05) (Figure 2d). 
Cardiac Function  
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Hemodynamic parameters of 30-week-old rats are shown in Table 3. LVSP as well as the 
values of (±) dP/dt were significantly reduced in the untreated control SHR group (p < 0.05); 
LVEDP was higher in SHR vs. WKY (p < 0.05). Oral administration of BMY 7378 or 
captopril improved hemodynamics in SHR (p < 0.05).  
Dose-response curves to isoproterenol were used to test cardiac function. Isoproterenol 
increased LVSP (Figure 3a) and LVEDP (Figure 3b) values in a dose-dependent manner in 
WKY rats,  while in SHR isoproterenol had no effect at any dose (p < 0.05). BMY 7378 
recovered the response to isoproterenol (p < 0.05). However, the change in LVSP was lower 
in comparison with that of WKY (p < 0.05) (Figure 3a), but LVEDP was not different (p > 
0.05) (Figure 3b). In a similar manner, captopril recovered the response to isoproterenol in 
LVSP and LVEDP (p < 0.05) (Figures 3a, 3b); but LVEDP was higher in comparison with 
WKY (p < 0.05) (Figure 3b). Absolute values of LV (±) dP/dt were significantly reduced in 
SHR (p < 0.05). Both were improved after treatment with BMY7 378 or captopril (p < 0.05), 
however there were still difference between treatments groups and normotensive control 
WKY (p < 0.05) (Figure 3c).  
Immunofluorescence 
The α1D-AR expression in cardiac muscle was abundant in SHR versus age-matched WKY 
(p < 0.05). Treatment with BMY 7378 induced expression of the receptor in SHR (p < 0.05 
versus untreated group). Captopril did not modify expression of α1D-AR in comparison with 





The SHR is a genetic model of human hypertension (23). It is known that SBP increases in 
SHR at around 5-10 weeks of age, while cardiac hypertrophy develops at 9-12 weeks of age 
(24). We found that SHR developed high blood pressure after week 10 and it was higher than 
those of WKY after 20 weeks of age. This was associated with development of cardiac 
hypertrophy, which was clearly evident at 20 weeks and severe at 30 weeks.   
After a stable period of compensatory hypertrophy supporting contractility in hypertension, 
SHR progress to heart failure with senescence (25). In the adaptation stage, LVH occurs as 
a response to normalize wall stress and to maintain pumping ability.  If pressure overload 
persists, hypertrophy becomes maladaptive with a progressive decline in LV contractility and 
diastolic function, as evidenced in SHR at 30 weeks where there was diminished LVSP and 
(+) dP/dt. These functional changes indicate damage in cardiac muscle and  loss in the ability 
of the heart to contract  (26). SHR had a higher value of LVEDP than WKY. In addition there 
was a decrease in (-) dP/dt, which is the maximal descent velocity (speed at which 
intraventricular pressure decreases during isovolumetric relaxation) and reflects the speed of 
relaxation of muscle fibers (27). Both parameters were modified in SHR indicating diastolic 
dysfunction. These phenomena were associated with reduced responses to isoproterenol and 
may predisopose to heart failure (28).  It is known that intrinsic impairment in the 
hypertrophied myocardial fibers, or diminished -ARs sensitivity due to high 
norepinephrine, are possible causes for this reduced cardiac responsiveness (29). In this 
context, we did not observe isoproterenol-induced contractility of SHR myocardium in 
contrast with the marked response in WKY rats, probably because 30-week-old SHR had 
severe concentric hypertrophy and great deposition of collagen between cells. We think that 
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this excess of ECM led to the formation of a fibrotic scar, avoiding the interaction of 
isoproterenol with 1-AR. 
To assess whether 1D-AR is involved in myocardial remodeling in hypertension, we 
compared effects of BMY 7378 vs. captopril (as positive control) in 30-week-old SHR with 
severe LVH, during 4 weeks. As expected, BMY 7378 decreased blood pressure, as well as 
left ventricular thickness and fibrosis, it regenerated the response to isoproterenol and 
improved heart´s contraction-relaxation as determined by (±) dP/dt, and significantly 
increased 1D-AR expression, which indicates that the antagonism of this receptor produces, 
at least in part, these reductions. Captopril showed the same actions as BMY 7378, which are 
in agreement with those reported in clinical studies, where ACE inhibitors and AT1R blockers 
revert LVH, decrease TGF-1 and reduce the ECM (30). 
Processes underlying these effects likely involve the RAS, important in HHD  (3,4,31,32), 
The RAS and adrenergic receptors interact as previously demonstrated (16). This may 
involve dimerization between 1D-AR and AT1R (33). Accordingly in conditions where Ang 
II is elevated, as in SHR and in the aryl hydrocarbon receptor null mouse (3,12,31), vascular 
1D-AR expression and function are increased, suggesting that both systems might be related 
with the onset of hypertension.  Furthermore, BMY 7378, which  has high affinity for 1D-
AR (pA2 = 8.9) (34), reversed the vascular hypertrophy generated by the continuous infusion 
of Ang II. It is thus possible that interaction between 1D-AR and the actions of Ang II-AT1R 
also play a role in  LVH in SHR (16). 
In conclusion these findings demonstrate that 1D-AR is involved in hypertension-associated 
cardiac hypertrophy. Mechanisms underlying this may involve the RAS and processes linked 
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to cardiac fibrosis. Since inhibition of 1D-AR with BMY 7378 also had blood pressure-
lowering effects, we can not exclude the possibility that prevention of LVH may be secondary 
to decreased blood pressure in SHR. Nevertheless, cardiac expression of 1D-AR was 
increased in SHR myocardium suggesting a possible direct effect in the heart. Our study 
defines a role for 1D-AR in cardiac remodeling in hypertension. 
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